Jun 2026 (Q2 FY26) — Aug 13, 2026
Cibus Q2 FY26 — Strategic Focus and Regulatory Tailwinds Amidst Rice Launch Delay
Read the full callCibus (CBUS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Cibus earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.99 | +6.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -1300.3 | +623.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -22.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.31 −0.76% · −$0.01
Performance −15.5% 1Y
1Y: $1.55 on 17 Oct 2025 → $1.31. High $4.05 (11 Mar 2026), low $1.16 (17 Nov 2025).
- Previous close
- $1.32
- 52-week range
- $1.16 – $4.05
- One year
- −21.08%
Overview
- Symbol
- CBUS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Cibus earnings calls (CBUS)
Financials
What the filings say
Net profit, year on year: +13% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Operating profit | -200 | -18 | -42 | -18 | -15 | -23 | -12 | -13 |
| Operating margin | −12023.8% | −1487.1% | −4020.4% | −1923.5% | −2510.2% | −2135.7% | −721.0% | −1300.3% |
| Profit before tax | -201 | -26 | -49 | -27 | -24 | -32 | -21 | -22 |
| Tax rate | −0.0% | −0.0% | 0.0% | −0.1% | 0.0% | −0.0% | −0.0% | −0.0% |
| Net profit | -180 | -23 | -47 | -25 | -24 | -31 | -21 | -22 |
| EPS ($ per share) | -7.63 | — | -1.34 | -0.61 | -0.44 | — | -0.33 | -0.29 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Reserves | -82 | -122 | -167 | -196 | -212 | -480 | -731 | -858 |
| Total liabilities | 25 | 26 | 26 | 23 | 15 | 206 | 252 | 283 |
| Fixed assets | 22 | 23 | 23 | 22 | 5 | 16 | 11 | 6 |
| Investments | — | 0 | 12 | 0 | 0 | — | — | — |
| Total assets | 119 | 88 | 63 | 37 | 22 | 544 | 350 | 305 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -20 | -32 | -44 | -19 | -19 | -46 | -58 | -51 |
| Cash from investing | -2 | -3 | -13 | 11 | -2 | 55 | -1 | -1 |
| Cash from financing | 61 | -0 | 15 | 4 | 10 | 20 | 41 | 47 |
| Net cash flow | 39 | -35 | -42 | -4 | -11 | 29 | -18 | -5 |
| Capital expenditure | -2 | -3 | -2 | -0 | -2 | -4 | -1 | -1 |
| Free cash flow | -22 | -35 | -45 | -19 | -21 | -51 | -59 | -51 |
Insider filings
20 filings between Nov 11, 2025 and Jun 8, 2026.
Open market
decisions to buy or sellNobody bought or sold CBUS on the open market in this window. The filings below are 11 awards and 9 tax withholdings.
Compensation
not trading decisions- 11
- Award — granted as compensation
- 9
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Wichner Craig CEO | Award | 894,309 | $0 |
| Jun 2, 2026 | Urban Thomas Director | Award | 64,748 | $0 |
| Jun 2, 2026 | Lehmann Jean-Pierre Jules Director | Award | 64,748 | $0 |
| Jun 2, 2026 | Prante Gerhard Director | Award | 64,748 | $0 |
| Apr 24, 2026 | Broos Carlo CFO | Award | 57,000 | $0 |
| Apr 24, 2026 | Gocal Gregory Francis William Chief Scientific Officer & EVP | Award | 57,000 | $0 |
| Apr 24, 2026 | Stokes Jason CAO, Gen Csl & Corp Secy | Award | 57,000 | $0 |
| Apr 24, 2026 | Sauer Noel Sr VP, Research | Award | 38,000 | $0 |
| Apr 24, 2026 | Beetham Peter Interim CEO, Pres & COO | Award | 195,000 | $0 |
| Mar 30, 2026 | Beetham Peter Interim CEO, Pres & COO | Tax withheld | 16,112 | $29.8K |
| Mar 30, 2026 | Gocal Gregory Francis William Chief Scientific Officer & EVP | Tax withheld | 8,954 | $16.3K |
| Mar 30, 2026 | Broos Carlo CFO | Tax withheld | 3,676 | $6.9K |
| Mar 30, 2026 | Stokes Jason CLO, Gen Csl & Secy | Tax withheld | 3,695 | $6.8K |
| Mar 30, 2026 | Sauer Noel Sr VP, Research | Tax withheld | 1,763 | $3.2K |
| Feb 19, 2026 | Stokes Jason CLO, Gen Csl & Secy | Tax withheld | 4,795 | $14.3K |
| Jan 29, 2026 | RIGGS RORY B Director | Award | 333,333 | $500.0K |
| Jan 29, 2026 | Lehmann Jean-Pierre Jules Director | Award | 666,666 | $1000.0K |
| Nov 11, 2025 | Sauer Noel Sr VP, Research | Tax withheld | 1,834 | $2.4K |
| Nov 11, 2025 | Broos Carlo CFO | Tax withheld | 1,496 | $2.0K |
| Nov 11, 2025 | Stokes Jason CLO, Gen Csl & Secy | Tax withheld | 3,519 | $4.6K |
| Jun 13, 2025 | Sauer Noel Sr VP, Research | Sale | 4 | $6 |
| Jun 9, 2025 | RIGGS RORY B Director | Option exercised | 4,000,000 | $400 |
| Jun 9, 2025 | RIGGS RORY B Director | Option exercised | 50,000 | $500 |
| Jun 5, 2025 | RIGGS RORY B Director | Award | 5,714,286 | $10.00M |
| May 22, 2025 | Prante Gerhard Director | Award | 32,490 | $0 |
| May 22, 2025 | Lehmann Jean-Pierre Jules Director | Award | 32,490 | $0 |
| Mar 24, 2025 | Sauer Noel SVP, Research | Award | 11,750 | $0 |
| Mar 24, 2025 | Stokes Jason CLO, Gen Csl & Secy | Award | 28,250 | $0 |
| Mar 24, 2025 | Gocal Gregory Francis William Chief Scientific Officer & EVP | Award | 60,000 | $0 |
| Mar 24, 2025 | Beetham Peter President and COO | Award | 125,500 | $0 |
| Mar 24, 2025 | Broos Carlo Interim CFO | Award | 28,250 | $0 |
| Feb 25, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.2K |
| Feb 24, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.4K |
| Feb 21, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.5K |
| Feb 20, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.7K |
| Feb 19, 2025 | Stokes Jason CLO, Gen Csl & Secy | Tax withheld | 4,795 | $11.1K |
| Feb 19, 2025 | Prante Gerhard Director | Sale | 1,150 | $3.0K |
| Feb 18, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.9K |
| Feb 18, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.9K |
| Feb 14, 2025 | Prante Gerhard Director | Sale | 1,150 | $3.0K |
| Feb 13, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.9K |
| Feb 12, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.8K |
| Feb 11, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.9K |
| Feb 10, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.9K |
| Feb 7, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.9K |
| Feb 6, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.9K |
| Feb 5, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.9K |
| Feb 4, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.8K |
| Feb 3, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.8K |
| Jan 31, 2025 | Prante Gerhard Director | Sale | 1,150 | $2.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Cibus, Inc.
Free account. Everything above stays public.
Write why you follow Cibus, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading